Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library

Wang,Wei; Chen,Tao; Li,Haicheng; Chen,Yuhui; Wu,Zhilong; Feng,Tongming; Zhang,Xilin; Zhong,Qiu; Zhong,Qianhong; Li,Guozhou; Guo,Lina; Zhou,Lin; Zhou,Jie

doi:10.3892/mmr.2015.4248

Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library

Authors:
- Wei Wang
- Tao Chen
- Haicheng Li
- Yuhui Chen
- Zhilong Wu
- Tongming Feng
- Xilin Zhang
- Qiu Zhong
- Qianhong Zhong
- Guozhou Li
- Lina Guo
- Lin Zhou
- Jie Zhou
View Affiliations

Affiliations: Department of Clinical Laboratory and Disease Control, Foshan Fourth People's Hospital, Foshan, Guangdong 528000, P.R. China, Department of Provincial Reference Laboratory and Disease Control, Center for Tuberculosis Control of Guangdong, Guangzhou, Guangdong 510630, P.R. China, Department of Clinical Laboratory, Chronic Disease Control and Prevention Station of Dongguan, Dongguan, Guangdong 523008, P.R. China, Department of Nutrition, Guangdong Provincial Hospital of Chinese Traditional Medicine, Guangzhou, Guangdong 510120, P.R. China
Published online on: August 25, 2015 https://doi.org/10.3892/mmr.2015.4248
Pages: 7051-7058

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has suggested that fibroblast growth factor 3 (FGF3) is expressed in breast cancer and correlates with the stage and grade of the disease. In the present study, a specific FGF3‑binding peptide (VLWLKNR, termed FP16) was isolated from a phage display heptapeptide library with FGF3. The peptide FP16 contained four identical (WLKN) amino acids and demonstrated high homology to the peptides of the 188‑194 (TMRWLKN) site of the high‑affinity FGF3 receptor fibroblast growth factor receptor 2. Functional analyses indicated that FP16 mediated significant inhibition of FGF3‑induced cell proliferation, arrested the cell cycle at the G0/G1 phase by increasing proliferation‑associated protein 2G4, suppressing cyclin D1 and proliferating cell nuclear antigen, and inhibited the FGF3‑induced activation of extracellular signal‑regulated kinase 1/2 and Akt kinase. Taken together, these results demonstrated that the peptide FP16, acting as an FGF3 antagonist, is a promising therapeutic agent for the treatment of breast cancer.

View Figures

View References

1	Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 8:235–253. 2009. View Article : Google Scholar : PubMed/NCBI
2	Mohammadi M, Olsen SK and Ibrahimi OA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107–137. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rusnati M and Presta M: Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 13:2025–2044. 2007. View Article : Google Scholar : PubMed/NCBI
4	Saxena R and Dwivedi A: ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev. 32:166–215. 2012. View Article : Google Scholar
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto M, Hosoda M, Nakano K, et al: p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci. 105:81–88. 2014. View Article : Google Scholar
7	Choi SY, Chang YW, Park HJ, Kim HJ, Hong SS and Seo DY: Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer. Brit J Radiol. 85:E474–E479. 2012. View Article : Google Scholar
8	van de Vijver MJ: Molecular tests as prognostic factors in breast cancer. Virchows Arch. 464:283–291. 2014. View Article : Google Scholar : PubMed/NCBI
9	Donegan WL: Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 47:28–51. 1997. View Article : Google Scholar : PubMed/NCBI
10	Dickson C, Spencer-Dene B, Dillon C and Fantl V: Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors. Breast Cancer Res. 2:191–196. 2000. View Article : Google Scholar
11	Grose R and Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16:179–186. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ and Mohammadi M: Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet. 13:2313–2324. 2004. View Article : Google Scholar : PubMed/NCBI
13	Penault-Llorca F, Bertucci F, Adélaïde J, Parc P, Coulier F, Jacquemier J, Birnbaum D and deLapeyrière O: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer. 61:170–176. 1995. View Article : Google Scholar : PubMed/NCBI
14	Wu XP, Huang HX, Wang C, Lin S, Huang Y, Wang Y, Liang G, Yan Q, Xiao J, Wu J, et al: Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget. 4:1819–1828. 2013. View Article : Google Scholar : PubMed/NCBI
15	Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
16	Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S and Pouysségur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA. 90:8319–8323. 1993. View Article : Google Scholar : PubMed/NCBI
17	Xia X, Cheng A, Lessor T, Zhang Y and Hamburger AW: Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol. 187:209–217. 2001. View Article : Google Scholar : PubMed/NCBI
18	Maga G and Hubscher U: Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci. 116:3051–3060. 2003. View Article : Google Scholar : PubMed/NCBI
19	Zhang JT and Liu Y: Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev. 33:741–756. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kandel E: Tumor-associated oncogenes go on (phage) display. Oncotarget. 1:84–85. 2010. View Article : Google Scholar
21	Ionov Y: A high throughput method for identifying personalized tumor-associated antigens. Oncotarget. 1:148–155. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bae DG, Kim TD, Li G, Yoon WH and Chae CB: Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clinical Cancer Res. 11:2651–2661. 2005. View Article : Google Scholar
23	Yardley DA, Hart L, Bosserman L, Salleh MN, Waterhouse DM, Hagan MK, Richards P, DeSilvio ML, Mahoney JM and Nagarwala Y: Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat. 137:457–464. 2013. View Article : Google Scholar :
24	Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther. 125:105–117. 2010. View Article : Google Scholar
25	Li Y, Hively WP and Varmus HE: Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 19:1002–1009. 2000. View Article : Google Scholar : PubMed/NCBI
26	Turnbull C, Ahmed S, Morrison J, et al: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 42:504–547. 2010. View Article : Google Scholar : PubMed/NCBI
27	Roy D and Calaf GM: Allelic loss at chromosome 11q13 alters FGF3 gene expression in a human breast cancer progression model. Oncol Rep. 32:2445–2452. 2014.PubMed/NCBI
28	Sherr CJ: G1 phase progression: Cycling on cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
29	Welsh CF, Roovers K, Villanueva J, Liu YQ, Schwartz MA and Assoian RK: Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol. 3:950–957. 2001. View Article : Google Scholar : PubMed/NCBI